Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced two senior executive hires in newly created roles as it prepares for its next stage of growth.

Denise Dettore joins as Chief People Officer and Jack Gold becomes Chief Marketing Officer. 

Dettore joins Absci with 26 years of experience in Human Resources in Silicon Valley, 10 years of which were in high-tech companies including Hewlett-Packard and Electronic Arts. For the past 16 years she has been working in the biotech industry, spending time at Genentech, Jazz Pharmaceuticals and BeiGene. At BeiGene, Dettore spent over three years as Vice President, Human Resources for North America, Europe and New Markets and Co-Global Head of Human Resources where she led a team implementing HR talent, infrastructure and culture initiatives while growing BeiGene from 700 colleagues to 8400 colleagues in less than four years.  

“The use of AI is the next evolution in precision medicine creation, and Absci is leading the charge in this space,” Dettore said. “In parallel with evolving the medicine development process, Absci has also created a unique and impressive, values-based and people-centric culture. I am excited to join as the Chief People Officer and work with the team to continue to build on Absci’s amazing culture and further scale the organization as it seeks to bring quality, lifesaving medicines to patients at unprecedented speeds.”    

Gold joins as Chief Marketing Officer to build and lead Absci’s marketing team and efforts. Gold was previously Chief Marketing Officer at Zymergen. Prior to Zymergen he spent 21 years at Nike serving in multiple senior marketing roles to help build the brand worldwide. Gold started his career in London at Saatchi & Saatchi, an eminent global advertising firm.

“I’m delighted to join a company as exciting and progressive as Absci and help put this pioneering brand on the map,” Gold commented. “Known for its game-changing AI technology and scientific expertise, Absci is advancing the field of drug discovery, and that’s important for human health. Mining nature’s vast canvas is hard, and we need breakthrough technologies now more than ever to discover new ways of making better drugs.”

“We are delighted to welcome an experienced HR head like Denise and a storied brand-builder like Jack to Absci,” said Sean McClain, founder and CEO of Absci. “Both of them have proven track-records of scaling successful businesses and organizational cultures while building attractive brands. We have been somewhat of a secret to date, but with Denise and Jack on board we are excited to embark on a new chapter of growth and elevate our unique company culture and storytelling - one protein at a time.” 

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Absci Forward-Looking Statements

Certain statements relating to Absci in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “aim,” “continue,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “objective,” “goal,” “estimates,” “expects,” “progress,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding technology development efforts, the effective incorporation of our technology in drug design, and corporate initiatives, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on strategic activities with our partners; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

​Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.